Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes

Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes

Bibliographic Details
Main Authors:	Jovanovič, Lois, Peters, Anne L., Jiang, Honghua H., Hardin, Dana S.
Format:	Online
Language:	English
Published:	Springer International Publishing 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955127/

Similar Items

Efficacy of insulin lispro in improving glycemic control in gestational diabetes
by: Deepaklal, M.C., et al.
Published: (2014)

Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery
by: Ahmad, Mushtaq, et al.
Published: (2015)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
by: Bhattacharyya, M, et al.
Published: (2007)

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials
by: Esposito, Katherine, et al.
Published: (2012)

Use of Insulin Lispro Protamine Suspension in Pregnancy
by: Lapolla, Annunziata, et al.
Published: (2015)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
by: Tinahones, F J, et al.
Published: (2014)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
by: Kumar, Ajay
Published: (2016)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
by: Rojas, Arturo, et al.
Published: (2016)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial
by: Barbieri, Douglas Eugenio, et al.
Published: (2015)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
by: de la Peña, Amparo, et al.
Published: (2015)

Insulin glargine overdose
by: Doğan, Fatma Sarı, et al.
Published: (2012)

Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
by: Blevins, T., et al.
Published: (2016)

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
by: Bergenstal, R. M., et al.
Published: (2016)

Isolation and Characterization of Acetylated Derivative of Recombinant Insulin Lispro Produced in Escherichia coli
by: Szewczak, Joanna, et al.
Published: (2015)

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
by: Arakaki, R F, et al.
Published: (2014)

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes
by: Pistrosch, F., et al.
Published: (2013)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
by: Hadjiyianni, I., et al.
Published: (2016)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
by: Steinstraesser, A, et al.
Published: (2014)

Comparison of thrice‐daily lispro 50/50 vs thrice‐daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes
by: Yamashiro, Keiko, et al.
Published: (2010)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
by: Belhekar, Mahesh N., et al.
Published: (2015)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
by: Stammberger, Ingo, et al.
Published: (2012)

A Salutary Tale—Glargine insulin and cancer risk
by: Boyle, Peter
Published: (2009)

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
by: Davies, M. J., et al.
Published: (2016)

Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease
by: LI, JILING, et al.
Published: (2014)

Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials
by: Curtis, Bradley H., et al.
Published: (2013)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
by: Ilag, L. L., et al.
Published: (2016)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
by: Lepercq, Jacques, et al.
Published: (2012)

Insulin glargine versus other types of basal insulin–clinical and tumor characteristics in patients with breast carcinoma
by: Besic, Nikola, et al.
Published: (2013)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
by: Stürmer, Til, et al.
Published: (2013)

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
by: Vora, J., et al.
Published: (2016)

Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes
by: Colatrella, Antonietta, et al.
Published: (2013)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
by: Meloni, Alison R, et al.
Published: (2013)

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK
by: Pratoomsoot, C, et al.
Published: (2009)

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
by: Uy, J, et al.
Published: (2012)

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals
by: Knadler, Mary Pat, et al.
Published: (2016)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
by: Rodbard, H W, et al.
Published: (2014)

Glargine and degludec: solution behaviour of higher dose synthetic insulins
by: Adams, Gary G., et al.
Published: (2017)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
by: Poon, Kitty, et al.
Published: (2010)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
by: Barnett, Anthony H
Published: (2006)

Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
by: Kadowaki, Takashi, et al.
Published: (2012)